Nutra Pharma Corporation (NPHC) Presenting at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference
Before the opening bell, Nutra Pharma Corporation (OTCQB: NPHC) announced that it will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference, which will take place at The Ritz-Carlton in Miami on South Beach on February 22, 2016. As a presenter, Nutra Pharma will be provided with a 30-minute time slot with which to present to an audience of investors and industry professionals. The company’s management team is also expected to be available for one-on-one meetings with institutional investors attending the event.
To view a complete list of presenting companies, visit http://steconference.com/presenting-companies
This announcement caps off what has been an eventful week for Nutra Pharma. On Tuesday, the biotechnology company announced the first of several growth steps expected to expand its core business strength, as well as its reach into important commercial markets. As part of this strategy, Nutra Pharma added Thomas W. Northrop, a member of New York-based management advisory and investment firm Tri-State Capital Partners, LLC, to its expanded management team. Northrop will serve as the company’s senior commercial development officer moving forward. From this position, he is expected to lead new marketing efforts in healthcare, governmental and military entities; aging athletes; and the elderly, as well as the completion of scientifically rigorous pain relief trials in multiple settings.
“The addition of Tom Northrop and TriState’s arrival as part of Nutra Pharma’s expanded management team are the first steps in the company’s growth strategy for 2016,” Rik J. Deutsch, chief executive officer of Nutra Pharma, stated in Tuesday’s news release. “With Tri-State’s support, we now have the tools and a depth of resources that will allow for expansion into multiple markets, as well as to help accelerate the development and deployment of our prescription drug candidates.”
Additional information regarding Nutra Pharma’s 2016 growth plans is expected to be announced in the coming weeks. With opioid abuse at record levels and heightened recognition of the potential dangers of misusing acetaminophen and non-steroidal anti-inflammatory drugs (NSAID), such as ibuprofen, the company will look to leverage its position in the biotechnology industry in order to capitalize on sizable global markets for innovative products addressing chronic pain.
Nutra Pharma operates as a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases – including multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN) and pain. The company also markets drug products for the treatment of chronic pain under the Nyloxin® and Pet Pain-Away brands.
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Before the opening bell, Nutra Pharma Corporation (OTCQB: NPHC) announced that it will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference, which will take place at The Ritz-Carlton in Miami on South Beach on February 22, 2016. As a presenter, Nutra Pharma will be provided with a 30-minute time slot with which to present to an audience of investors and industry professionals. The company’s management team is also expected to be available for one-on-one meetings with institutional investors attending the event.
To view a complete list of presenting companies, visit http://steconference.com/presenting-companies
This announcement caps off what has been an eventful week for Nutra Pharma. On Tuesday, the biotechnology company announced the first of several growth steps expected to expand its core business strength, as well as its reach into important commercial markets. As part of this strategy, Nutra Pharma added Thomas W. Northrop, a member of New York-based management advisory and investment firm Tri-State Capital Partners, LLC, to its expanded management team. Northrop will serve as the company’s senior commercial development officer moving forward. From this position, he is expected to lead new marketing efforts in healthcare, governmental and military entities; aging athletes; and the elderly, as well as the completion of scientifically rigorous pain relief trials in multiple settings.
“The addition of Tom Northrop and TriState’s arrival as part of Nutra Pharma’s expanded management team are the first steps in the company’s growth strategy for 2016,” Rik J. Deutsch, chief executive officer of Nutra Pharma, stated in Tuesday’s news release. “With Tri-State’s support, we now have the tools and a depth of resources that will allow for expansion into multiple markets, as well as to help accelerate the development and deployment of our prescription drug candidates.”
Additional information regarding Nutra Pharma’s 2016 growth plans is expected to be announced in the coming weeks. With opioid abuse at record levels and heightened recognition of the potential dangers of misusing acetaminophen and non-steroidal anti-inflammatory drugs (NSAID), such as ibuprofen, the company will look to leverage its position in the biotechnology industry in order to capitalize on sizable global markets for innovative products addressing chronic pain.
Nutra Pharma operates as a biotechnology company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases – including multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN) and pain. The company also markets drug products for the treatment of chronic pain under the Nyloxin® and Pet Pain-Away brands.
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
